Salvage therapy with amprenavir and ritonavir: prospective study in 17 heavily pretreated patients.
OBJECTIVE
To evaluate the safety profile and efficacy of salvage regimens containing amprenavir (APV) 600 mg twice daily and ritonavir (RTV) 200 mg twice daily.


METHODS
Prospective, single-center study.


METHODS
The patient database of the department of infectious diseases was screened for patients who had failed at least two successive three-drug combinations. These patients were proposed to take APV and RTV in association with two to four other drugs. They were followed monthly for 6 months.


RESULTS
Seventeen patients were included. They had been previously treated for 70 +/- 23 months. At baseline, viral load (VL) was 4.86 +/- 0.98 log10 copies/mL and CD4 187 +/- 145 10(6)/L. On week 24, using intent-to-treat analysis, VL decreased to 2.95 +/- 1.59 log10 copies/mL and CD4 increased to 365 +/- 210 10(6)/L. Nine patients (53%) had a VL < 2.3 log10 copies/mL. The most common adverse events were grade 1 or 2 diarrhea and an increase of cholesterol and triglyceride levels. Mean APV trough concentration was 1727 +/- 1749 ng/mL on week 24.


CONCLUSIONS
These data show that the combination of low-dose RTV and reduced doses of APV is safe. This combination can be added to nonnucleoside analogs.
Arvieux
Cédric
C
Service des Maladies Infectieuses et Réanimation Médicale, Centre Hospitalier et Universitaire de Rennes, Rennes, France. Cedric.Arvieux@chu-rennes.fr
Tattevin
Pierre
P
Souala
Faouzi M
FM
Jaccard
Philippe
P
Ruffault
Annick
A
Bentué-Ferrer
Danielle
D
Tribut
Olivier
O
Chapplain
Jean-Marc
JM
Dupont
Mathieu
M
Bouvier
Cécile
C
Michelet
Christian
C
D000328:Adult; D019380:Anti-HIV Agents / Q000009:adverse effects / Q000627:therapeutic use*; D018791:CD4 Lymphocyte Count; D002219:Carbamates; D024882:Drug Resistance, Viral / Q000235:genetics; D004359:Drug Therapy, Combination; D005260:Female; D005663:Furans; D005838:Genotype; D015658:HIV Infections / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D015497:HIV-1 / Q000187:drug effects / Q000235:genetics / Q000276:immunology; D006801:Humans; D008297:Male; D008875:Middle Aged; D010349:Patient Compliance; D010641:Phenotype; D011446:Prospective Studies; D019438:Ritonavir / Q000009:adverse effects / Q000627:therapeutic use*; D016879:Salvage Therapy; D013449:Sulfonamides / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome; D019562:Viral Load
D019380:Anti-HIV Agents; D002219:Carbamates; D005663:Furans; D017320:HIV Protease Inhibitors; D013449:Sulfonamides; C095108:amprenavir; D019438:Ritonavir